Citius Oncology, Inc. (CTOR) announced it has been granted an extension by the Nasdaq Stock Market to regain compliance with the minimum $1.00 bid price requirement. The company now has until April 19, 2027, to meet the listing standard, avoiding immediate delisting.
Key Details
- Compliance Deadline: The extension provides the company until April 19, 2027, to satisfy the Nasdaq Listing Rule 5550(a)(2).
- Compliance Requirement: To regain compliance, the company's common stock must have a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.
- Current Status: The extension has no immediate effect on the stock's listing, and it will continue to trade on The Nasdaq Capital Market under the symbol "CTOR". If compliance is not achieved by the deadline, the company will receive a delisting notice.